Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
You may also be interested in...
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
With its HIV portfolio benefitting from a post-pandemic recovery, the drug maker said demand for Biktarvy drove higher US and Europe sales, while oncology products saw growth of 79% year-over-year.